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Abstract 
 
 A significant challenge facing the Air Force Medical Service (AFMS) Military 
Treatment Facilities (MTFs) is the perishability costs associated with its pharmaceutical 
stock.  During a two year time period, the AFMS returned expired or nearly expired 
pharmaceuticals valued at over $23,000,000.  In response to the waste represented by 
pharmaceutical perishability cost, this thesis analyzes the historical inventory 
management decisions of 173 MTF/pharmaceutical combinations and proposes an 
alternative inventory control policy to reduce perishability costs.  Based on the critical 
nature of pharmaceuticals and importance of generating high patient satisfaction, the 
proposed alternative inventory control system was required to be cognizant of the cost 
savings/service level trade-off.  After applying a fundamental inventory management 
equation to historical patient demands, the calculated inventory control policy is 
evaluated against a recent nine month time period of patient demand in terms of potential 
cost savings and fill rates.  At the conclusion of the study, it is determined that the use of 
the proposed inventory control policy would generate an effective perishability cost 
savings of approximately $250,000 annually, as well as a one-time inventory reduction 
cost savings that exceeds $1,700,000.  In spite of this stock reduction, the studied 
MTF/pharmaceutical combinations would maintain a strong fill rate that exceeds 99.82%. 
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I.  Introduction 
Background 
 As the United States’ (U.S.) debt position soars past eighteen trillion dollars 
(www.usdebtclock.org), pressures continue to mount in favor of reduced federal 
spending.  Based on this sentiment, the Future Year Defense Program (FYDP) budget 
has become a target of considerable scrutiny.  This is primarily based on the fact that the 
Department of Defense (DoD) consumes the largest portion of the federal government’s 
discretionary spending authority. Receiving the most scrutiny within the DoD budget is 
the unsustainable growth of personnel costs.  The Secretary of Defense (SECDEF) 
weighed in on the issue during a speech that he delivered to the Center for Strategic and 
International Studies on November 5, 2013.  
Without serious attempts to achieve significant savings in this area [military 
personnel costs] — which consumes roughly half of the DoD budget and is 
increasing every year — we risk becoming an unbalanced force ... one that is 
well-compensated, but poorly trained and equipped, with limited readiness and 
capability. 
      Chuck Hagel, 
      Secretary of Defense (2013) 
 
 Military personnel costs accounted for approximately 130 billion dollars of the 
overall 512 billion dollar fiscal year (FY) 2014 DoD budget (Office of Management and 
Budget, 2013).  While military personnel costs are comprised of significant budgetary 
line items such as base pay, allowances, and retired pay accrual, it is the rapid escalation 
of defense related healthcare costs that has led many to conclude that current policies are 
unsustainable (Rugy, 2014).  Figure 1 displays the breakdown of the 49.4 billion dollar 
FY 2014 budget associated with military healthcare costs, accounting for approximately 
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9.39 percent of the overall defense budget.  This current portion of the overall defense 
budget is up from approximately 6 percent in FY 2000. 
 
Figure 1:  FY 2014 Unified Medical Budget Request ($billions) 
The most alarming aspect of the defense healthcare cost is that it is projected to 
expand at a rate much higher than other defense related costs.  The Congressional 
Budget Office (CBO) projects that the defense healthcare cost will skyrocket to 95 
billion dollars by FY 2030, accounting for over 14% of the nation’s projected defense 
requirement of the same year (Jansen, 2014:17).  Figure 2 displays a graphical 
representation of the CBOs projection of defense related healthcare costs consuming 
larger portions of the overall defense budget in future years.   
An additional challenge facing the DoD is the Budget Control Act of 2011, which 
constrains defense related spending through the year 2021.  In this fiscally constrained 
environment, the continuation of rapidly escalating healthcare costs could force the DoD 
to make difficult tradeoff decisions and reduce spending in areas such as force structure, 
military readiness, and weapons modernization (Congressional Budget Office, 2014).  
These types of actions have become reality with the President’s proposed 2015 defense 
budget calling for a reduction in force structure across all military services along with 
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the retirement and cancellation of other weapon systems (Simeone, 2014).   Current 
strategies to control the DoD’s rising healthcare costs have largely focused on proposals 
that shift financial burdens to military personnel by raising enrollment fees, deductibles, 
or copayments (Rugy, 2014).  While these measures may prove to be necessary in 
sustaining future military capabilities, the DoD must first perform a fundamental review 
of its healthcare delivery methods in search of opportunities that increase efficiencies 
while maintaining a high level of service for its beneficiaries. 
 
Figure 2:  Future Year Projection of Healthcare Costs as a Percentage of the DoD Budget 
Problem Statement 
 One healthcare delivery method that is fitting of such a fundamental review is the 
distribution of pharmaceuticals.  Pharmaceuticals are a primary contributor to the 
escalating healthcare costs shouldered by the DoD.  The DoD’s pharmaceutical costs 
have expanded from approximately three billion dollars in 2002 to approximately 6.8 
billion dollars in 2011, outpacing the overall pharmaceutical sales rate in the U.S. by 
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nearly double.  To put this into perspective, the DoD spent more resources on 
pharmaceuticals than it did on Black Hawk helicopters, Abrams tanks, Hercules C-130 
cargo planes and Patriot missiles—combined (Schwartz & McDonald, 2013). 
 The DoD provides pharmaceutical benefits to its eligible beneficiaries by means 
of three distinct delivery methods.  These three methods include local retail pharmacies, 
mail-order service, and DoD Medical Treatment Facility (MTF) distribution.  Studies 
have shown that pharmaceuticals delivered through the retail pharmacy method cost the 
DoD more than when the same pharmaceuticals are delivered through the mail-order and 
MTF distribution methods (Rand Corporation, 2005).  The primary reason that the MTF 
distribution method is most cost effective on a per prescription basis is that it utilizes a 
prime vendor for all pharmaceutical supplies.  On January 25, 2005, the Defense 
Logistics Agency (DLA) awarded the Pharmaceutical Prime Vendor (PPV) Generation 
III contract to AmerisourceBergen Drug Corporation for TRICARE regions North and 
South and to Cardinal Health Inc. for TRICARE West (Defense Logistics Agency, 
2014).   
 The PPV Generation III contract provides multiple benefits to the MTFs of all 
military branches.  One of the key benefits of the contract is the ten year pricing 
agreement with declining distribution fees as the contract ages.  It is the combined 
purchasing power of all DoD MTFs across the Contiguous United States (CONUS) and 
the pricing agreement included in the PPV Generation III contract that enables the MTF 
pharmacies to dispense prescriptions to TRICARE beneficiaries in a cheaper manner 
than their retail counterparts.  Additionally, the PPV Generation III contract provides 
contractual fill rates that range between 95 and 98 percent and include a one business 
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day delivery lead time.  Although the PPVs are contractually responsible for filling 95 to 
98 percent of MTF’s daily pharmaceutical requirements, their historical performance has 
far exceeded this obligation.  A secondary “back-up” contract is also in place to be 
utilized in the event that the PPV cannot fill an MTF requirement (Defense Logistics 
Agency, 2014).  The high fill rates and shortened delivery lead times afforded by the 
PPV Generation III contract should be leveraged by the MTFs to reduce their respective 
pharmaceutical inventories. 
Despite this fact, there is evidence to suggest that Air Force Medical Service 
(AFMS) MTFs have not seized this opportunity to reduce pharmaceutical inventories.  
Per the Air Force Medical Operations Agency (AFMOA)/SGAL office, the aggregated 
value of pharmaceutical inventory positions across all Air Force MTFs is in excess of 
134 million dollars.  The same AFMOA/SGAL office estimates that the aggregated 
inventory position across all AFMS MTFs should be closer to a value of 32 million 
dollars.  Perhaps the most alarming evidence suggesting that the AFMS currently holds 
too much pharmaceutical inventory is based on the fact that it returned a significant 
amount of pharmaceuticals that were either past its expiration date of clinical 
effectiveness or nearing the expiration date.  Over the two year time period of September 
2012 through September 2014, these returns were valued at over 23 million dollars.   
While the PPV Generation III contract provides a mechanism for MTFs to recoup 
approximately 40 percent of the sale price for the return of pharmaceuticals with a 
remaining lifespan of clinical effectiveness, the pharmaceuticals returned through the 
reverse distribution vendor represent waste within the process. 
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Research Objectives/Questions 
 Given the problem, the purpose of this study is to identify an ordering policy that 
would reduce the AFMS’ pharmaceutical inventory position, while maintaining a high 
level of patient prescription fill rates.  The overarching objective is to demonstrate a 
potential for cost savings that can be achieved through a sound ordering control policy 
and the execution of inventory management procedures applied to the AFMS’ 
pharmaceutical supplies.  In the pursuit of this objective, three research questions will be 
addressed: 
1. What cost savings can the AFMS realize in terms of reducing the amount of 
expired or near expired pharmaceutical returns, given the application of an 
inventory control system that utilizes adjusted order-up-to stock level quantities?  
 
2. What cost savings can the AFMS realize in terms of reducing on-hand 
pharmaceutical stock, given the application of an inventory control system that 
utilizes adjusted order-up-to stock level quantities? 
 
3. What impact will the proposed inventory control system have on pharmaceutical 
fill rates? 
Methodology 
 This study uses a multiple phased methodology approach to address its three 
research questions.  As with most research efforts, the initial phase of this study 
consisted of collecting pertinent data sets.  The first set of data collected was that of the 
AFMS pharmaceutical returns over a two year time period.  Along with providing the 
motivation for the study altogether, the pharmaceutical returns data was used to focus 
the study on the inventories of 32 distinct pharmaceuticals across all CONUS MTFs.  
Because not all CONUS MTFs recorded returns of the 32pharmaceuticals, the study 
performed inventory analysis that culminated over 173 MTF/pharmaceutical 
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combinations.  Additionally, patient pharmaceutical demand records, PPV sourcing 
records, and the Defense Medical Logistics Standard Support (DMLSS) Customer Area 
Inventory Management (CAIM) suggested levels were collected for use in subsequent 
phases of the methodology. 
 The next phase of the methodology consists of constructing an estimate of the 
historical inventory positions for the respective MTF/pharmaceutical combinations.  
This estimation is a necessary step based on the actual inventory positions not being 
available for use in this study.  Therefore, an estimated daily timeline of historical 
inventory positions for the respective MTF/pharmaceutical combinations were 
constructed by using the daily patient demand records, PPV sourcing records, and the 
number of units returned to the reverse logistics vendor.   
The primary challenge with the reconstruction of the daily inventory positions 
was the absence of a starting inventory position on the first day of analysis (1/1/2012).  
In lieu of the actual starting inventory position, the study used the DMLSS CAIM 
suggested level for its starting inventory position.  The one exception to using the CAIM 
suggested level takes place if that level allows the inventory position to fall below zero, 
signifying a stockout.  Because the patient demand data is actually representative of the 
prescriptions filled by the MTF pharmacies, stockouts were not permitted in the 
recreation of the historical inventory positions.  In these cases, the starting inventory 
position was raised to the minimum level that ensured zero stockouts occurred in the 
historical reconstruction of the inventory positions.  
The third phase of the methodology consists of calculating an alternative order-
up-to stock level for each of the respective MTF/pharmaceutical combinations.  A basic 
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inventory management equation is applied to the 1/1/2012 through 12/31/2013 patient 
demand data to determine an appropriate order-up-to stock level.  Upon the completion 
of these calculations, the alternative order-up-to stock levels are evaluated with respect 
to the patient demand data under the time period of 1/1/2014 through 9/19/2014.  The 
alternative order-up-to stock levels are evaluated in terms of cost savings and 
pharmaceutical fill rates, thereby providing answers to the study’s three research 
questions. 
Assumptions 
The primary assumption of the study is that the collected data is accurate and 
representative of the actual pharmaceutical inventory transactions that took place over 
the three year span.  This is a reasonable claim, based on the fact that the data sets were 
collected directly from their official record keeping systems (i.e., DMLSS and the 
Military Health System Management Analysis and Reporting Tool).  The study also 
makes three additional assumptions in an effort to reduce complexity within the 
inventory analysis.   
The first of these assumptions is that the research effort will use a fixed value of 
six months to represent the individual pharmaceutical’s lifespan of clinical effectiveness 
in the inventory analysis. The six month value was chosen based on the fact that it 
represents the shortest acceptable lifespan of a newly supplied pharmaceutical as 
prescribed in the PPV Generation III contract.  This life expectancy assumption 
undertakes a conservative approach, based on it representing the worst case scenario.   
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The second assumption found within the study is that it treats the delivery lead 
time of all pharmaceuticals as a deterministic value of one business day.  This 
assumption was based on the PPV Generation III contract parameters and the vendor’s 
historical demonstration of meeting this requirement on nearly all occasions.  The final 
assumption of the study is that the inventory model will assume a First-In First-Out 
(FIFO) distribution policy.  This is common practice of all pharmacies, where the newest 
pharmaceuticals are placed behind older pharmaceuticals in the pharmacy shelving. 
Limitations  
Based on time and data constraints, this study possesses three limitations that 
must be considered.  The first limitation is that the study will focus on only the 
pharmaceutical inventory management practices of Air Force (AF) MTFs within the 
CONUS.  While many of the principles introduced in this study are applicable to the 
MTFs of other military services and MTFs Outside [the] Contiguous United States 
(OCONUS), the results found in this study cannot be generalized to those MTFs.  
The second limitation found within the study is that analysis could not feasibly be 
performed on the 15,098 distinct pharmaceuticals that were returned by AFMS MTFs 
over the two year period.  While the study performs analysis on only 32 of these 
pharmaceuticals, an attempt to reduce this limitation was made by focusing on the 
pharmaceuticals that exhibited the greatest portion of returns as measured by dollar 
value.   
The third limitation found within the study is that patient demand, PPV sourcing, 
and returns data is aggregated across all pharmacies operating under the authority of a 
 
10 
MTF.  This is a potential limitation to the study based on the common practice of most 
MTFs operating a main pharmacy within the primary clinic facility, while also operating 
a “refill” pharmacy that is typically located in an area near the Base Exchange or 
Commissary.  While this limitation has the potential to affect the savings and fill rate 
calculations, the magnitude of the loss in precision should be minimal. 
Implications 
The Department of Defense is facing a legitimate challenge in the form of rising 
healthcare costs.  As referenced before in the background section of this chapter, the 
CBO projects that the defense healthcare cost will skyrocket to $95 billion by the year 
2030, accounting for over 14% of the nation’s projected defense requirement in the same 
year (Jansen, 2014).  As healthcare costs are projected to surge within the Department of 
Defense budget, civilian and military leaders will be forced to choose between a 
potential reduction in healthcare benefits for beneficiaries or a reduction in war fighting 
capabilities (personnel and weapon systems).  The only solution to avoiding this 
unenviable position is to reduce or at the very least slow the growth of military 
healthcare costs.   
 While this study in pharmaceutical supply operations does not intend to present 
the grand illusion of solving the challenge of rising healthcare costs in one fell swoop, it 
does provide a starting point from which to begin.  Along with the modest cost reduction 
that the proposed research study intends to accomplish, it will also provide momentum 
for additional research within the Air Force Medical Service to be initiated.   
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Thesis Organization 
 This thesis is comprised of five chapters.  Chapter 2 provides a summary of extant 
literature that is relevant to the research questions posed in Chapter 1.  The summary of 
relevant literature is further categorized into the inventory management of non-
perishable items with deterministic demand, non-perishable items with stochastic 
demand, non-specific perishable items, perishable blood donations, and concludes with 
the inventory management of perishable pharmaceuticals.  Chapter 3 summarizes the 
methodology used in this research effort.  The primary phases of the methodology 
include data collection, estimation of historical inventory positions, the calculation of an 
alternative order-up-to stock level, and concludes with an evaluation of the alternative 
order-up-to stock level.  Chapter 4 presents the results and analysis of the performed 
methodology.  Chapter 5 provides a summary of the study by answering the research 
questions and concludes the thesis with recommendations for action and future research. 
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II. Literature Review 
Chapter Overview 
The inventory management discipline has been studied extensively by operations 
research analysts and practitioners alike.  The primary objective of the inventory 
management discipline is for an organization to determine inventory policies for 
individual products that result in the maximum net benefit.  In other words, the 
organization seeks the optimal levels of inventory that allows for the fulfillment of 
customer demand while also limiting the costs associated with holding excess inventory.  
The study of inventory management can be separated into two categories; products 
exhibiting indefinite or long term life expectancies and products possessing fixed finite 
life expectancies.  The products possessing fixed finite life expectancies are commonly 
referred to in the extant literature as perishable items.  Examples of perishable items 
include amongst others: grocery items, seasonal fashion items, blood donations, and 
pharmaceuticals.   
Despite the perishability factor of pharmaceuticals, this literature review will 
begin by briefly introducing the contributions of early studies focusing on the derivation 
of optimal inventory management policies for non-perishable products.  The decision to 
include non-perishable inventory management studies stems from the fact that these 
studies set the foundation for the much more complex studies of perishable inventory.  
The literature review of non-perishable inventory management studies will be separated 
into those with a deterministic product demand rate and those with a stochastic product 
demand rate.  
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Upon the completion of the non-perishable inventory management section, the 
remaining focus of this chapter will be to review the extant literature that is associated 
with the inventory management of perishable products.  The remaining review of extant 
literature on the inventory management of perishable products will be separated into 
three sections.  The first section will introduce studies that pertain to the general 
discipline of perishable inventory management.  This section will include the 
fundamental studies that provided the foundation for expanded studies that specifically 
address the inventory management policies of perishable items related to the effective 
and efficient delivery of healthcare.   
The second section of the remaining literature review will introduce the extant 
research that focuses on the management of blood donation inventories.  Soon after the 
fundamental ground work for the discipline of perishable inventory management was 
set, the inventory operations of blood banks became a popular topic amongst operations 
research analyst.  One explanation for the popularity of the blood bank research stems 
from the high stakes that are associated with whole blood availability for transfusions 
and other medical procedures.  The literature review will conclude with an introduction 
to the extant research conducted on the inventory management practices of 
pharmaceuticals.  While studies on pharmaceuticals have not yet reached the prevalence 
attained by blood bank research, it is growing in response to the significance that 
pharmaceuticals play in the overall cost of healthcare delivery. 
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Inventory Management of Non-Perishable Items with Deterministic Demand 
Perhaps the most fundamental paradigm in the discipline of inventory 
management ensued with Ford Whitman Harris’ derivation of the Economic Order 
Quantity (EOQ) calculation.  In his article, titled How Many Parts to Make At Once, 
Ford Whitman Harris describes an economic quantity calculation for determining the 
optimal production lot size for the manufacturing industry (Harris, 1913).  While there is 
some debate over who was the first to expand Harris’ original work on the EOQ, it was 
quickly modified and applied to the inventory control problem of determining the 
optimal order quantity for an individual product (Erlenkotter, 1990).  Harris’ basic EOQ 
model requires underlying assumptions to be made upon the circumstances of the 
inventory item being analyzed (Silver, Pyke, & Peterson, 1998).  Table 1 displays the 
eight underlying assumptions of the EOQ model below: 
Table 1:  Underlying Assumptions of the EOQ Model 
EOQ Assumptions 
●  The product demand rate is constant and deterministic 
●  There are no minimum or maximum restrictions on the size of an order 
●  The unit variable cost is fixed 
●  The cost factors do not change with time 
●  No shortages/backorders are permitted 
●  The delivery lead time for a product is fixed 
●  The entire order quantity is delivered at the same time 
●  Substitutions of products are not permitted 
 
Given these assumptions, the basic EOQ model determines the order quantity that 
minimizes the total cost by assessing the tradeoff between a fixed ordering cost and a 
holding cost represented as a percentage of the unit variable cost in stock (Muckstadt & 
Sapra, 2010).  Figure 3 displays the fixed and holding costs as functions of the optimal 
order quantity (Q*).   
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Figure 3:  Fixed and Holding Costs Functions of the Order Quantity (Muckstadt & 
Sapra, 2010) 
The basic EOQ formula is then given as: 
EOQ = �2𝐾𝜆
𝐼𝐶
       (1) 
Where 
  K = Fixed Order Cost 
 
  λ = Annual Demand Rate of the Product 
 
  I = Holding Cost (% of unit variable cost) 
 
  C = Unit Variable Cost 
 
With the optimal order quantity calculated with respect to the underlying 
assumptions, the final piece of the inventory control policy needed is the determination 
of the reorder point.  Since the on hand inventory position of an item is assumed to be 
zero upon replenishment, the inventory level upon which a replenishment order is 
requested is equal to the demand of the product (λ) during the lead time (τ) of the 
replenishment.  Therefore, the reorder point (r) for the basic EOQ model is equal to λτ. 
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Inventory Management of Non-Perishable Items with Stochastic Demand 
While the EOQ is regarded as the fundamental paradigm for the inventory 
management discipline, it is often criticized for its restrictive underlying assumptions.  
The main assumption of the basic EOQ model that does not correspond with reality is 
the assumption of the product demand exhibiting a constant and deterministic rate.  In 
reality, the product demand rate is stochastic.  With a stochastic product demand rate, 
the organization must forecast the product demand rate while also accounting for the 
variability of the forecast by including a safety stock level to buffer against the threat of 
a product stockout.   
The two most common approaches to determining a safety stock level are through 
a basis of minimizing cost as well as a basis of meeting a predetermined customer 
service level (Silver, Pyke, & Peterson, 1998).  The approach based on minimizing cost 
explicitly or implicitly assigns a cost to a stockout occurrence and then attempts to 
minimize the total cost by assessing the tradeoff between the stockout cost and the 
holding cost of excess inventory.  The approach based on meeting a predetermined 
customer service level uses statistical analysis of the product demand lead time to 
determine the appropriate safety stock level that is necessary to attain or exceed the 
service level constraint.   
Facing the reality of a stochastic product demand rate, the majority of non-
perishable inventory management literature focuses on the derivation of optimal or near-
optimal stock levels with regards to three common inventory control policies (Silver, 
Pyke, & Peterson, 1998).  The first inventory control policy is referred to as the Order-
Point, Order-Quantity (s, Q) policy.  This inventory control policy features a fixed 
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quantity (Q) being ordered whenever the inventory position of an individual product 
drops below the reorder point (s).  The second policy is referred to as the Order-Point, 
Order-Up-To level (s, S) policy.  Similar to the previous (s, Q) inventory control policy, 
the (s, S) policy places a replenishment order when the individual products inventory 
position drops below the reorder point (s).  The difference between the two policies is 
that the (s, S) policy places a replenishment order with a variable quantity that equals the 
difference between the order-up-to level and the net inventory position.   
The third and final inventory control policy that is commonly found in the extant 
literature is referred to as the Periodic-Review, Order-Up-To-Level (R, S) policy.  The 
(R, S) policy has a predetermined time interval for reviewing the inventory position of 
an individual product (i.e., once a day, once a week, etc.).  During this periodic review 
of the inventory position, a replenishment order is made in the amount equal to the 
difference between the Order-Up-To-Level (S) and the individual product’s net 
inventory position.  This is essentially the inventory control policy used by AFMS 
pharmacies.   
Inventory Management of Non-Specific Perishable Items  
 One of the fundamental contributors to the research of perishable inventory 
management practices is Dr. Steven Nahmias of Santa Clara University.  In one of his 
earliest works, entitled Optimal Ordering Policies for Perishable Inventory―II, 
Nahmias (1975) develops a single period model for a single perishable product where an 
assumption is made that replenishment orders are placed at the beginning of each period 
and are received instantaneously (no positive lead time).  In pursuit of minimizing costs 
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associated with various ordering policies, the overall cost of the inventory policy is 
charged linearly for ordering, holding, stockout, and expiration costs.  When Nahmias 
attempts to derive the optimal ordering policies of a single perishable product in a multi-
period time horizon, he finds that with the exception of products with very short life 
expectancies, the computations are not realizable. 
 Nahmias (1982) followed this study by completing a summary and review of the 
extant research in the field of perishable inventory theory up until the 1982 date of 
publishing.  Nahmias begins by distinguishing the attribute of inventory perishability as 
either fixed lifetime or random lifetime.  Since the expiration date associated with all 
pharmaceuticals represents a definitive date of clinical effectiveness, the author’s review 
of fixed life perishability is most pertinent to the AFMS pharmaceutical research effort.  
Nahmias’ study further categorizes fixed life perishability into deterministic and 
stochastic product demands.  Nahmias begins by reviewing research applying a periodic 
review with known demand, as found in a dissertation effort by A. F. Veinott (1960).  
Unfortunately, these assumptions are not practical for application based on the 
occurrence of demand changing over time in reality.   
Nahmias proceeds to introduce the research that had been conducted on 
perishable products with stochastic demand.  Echoing a conclusion from his previous 
work, he states that when demand is stochastic and the life expectancy of the product 
exceeds one period, the computation of optimal ordering policies is extremely difficult.  
Nahmias acknowledges the first researcher to tackle a two period life expectancy 
problem was G. J. Van Zyl.  Van Zyl (1964) modeled the two period life expectancy 
product with respect to the proportional costs of ordering and stockouts.  Similarly, 
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Nahmias and Pierskalla (1973) modeled the two period life expectancy product with 
respect to the costs of stockouts and product expiration.   
Expansion of the research into inventory optimization models for perishable 
products exceeding a fixed life expectancy that was greater than two periods was 
developed simultaneously and independently by Fries (1975) and Nahmias (1975).  
Their research showed that an increase of initial stock of inventory of any age by one 
unit will decrease the optimal order quantity by less than a single unit.  Despite this 
finding, the researchers found that the computational time of using either model for 
product life expectancies greater than or equal to three periods is difficult and 
impractical for a real problem. 
 Nahmias later teamed up with Charles P. Schmidt (1985) to study the modeling of 
(S-1, S) policies for a single perishable item with a fixed and known life expectancy.  A 
(S-1, S) inventory control policy suggests that an order is placed for exactly one unit at 
each occurrence of a product demand and at each occurrence of a product expiration in 
the case of perishable items.  The significance of this study is that it was the first of its 
kind to incorporate a positive lead time for product replenishment.  Using this model, 
Schmidt & Nahmias display a sensitivity analysis that demonstrates the impacts of 
various levels of product life expectancy and replenishment lead times on the optimal 
value of S, as well as the expected annual cost for the indicated parameters.  The early 
works by Nahmias and other pioneers in the study of perishable inventory management 
laid the groundwork for others to expand upon their work and focus on specific 
assumptions and control models of perishable inventory.   
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 B. C. Giri & K. S. Chaudhuri (1998) pursue an EOQ-type inventory model 
approach with a demand rate that is dependent on the on-hand inventory stock level of 
the specified perishable product.  This is based on the Levin et al. (1972) research that 
suggested "at times, the presence of inventory has a motivational effect on the people 
around it.  It is a common belief that large piles of goods displayed in a supermarket will 
lead the customer to buy more".  The primary significance of the Giri & Chaudhuri 
article is that they treat the holding cost parameter of the EOQ model as a nonlinear 
function of the length of time for which the item is held in stock. 
 Liming Liu & Zhaotong Lian (1999)  expand the body of knowledge by analyzing 
a (s, S) continuous review perishable inventory model with a general renewal demand 
process and instantaneous replenishment of ordered stock.  Inspired by a lack of extant 
literature addressing the optimization of a continuous review perishable inventory 
model, the Liu & Lian use a Markov renewal approach to obtain closed-form solutions 
for the steady state probability distribution of the inventory level.  Additionally, the Liu 
& Lian use a closed-form expected cost function to study the impact of various 
parameters.  The Liu & Lian study concludes that because the distribution of the 
objective function is not affected by the coefficient of variation of the demand process, it 
is reasonable to believe that the (s, S) policy is the optimal model for general renewal 
demand processes.   
 Hideki Katagiri & Hiroaki Ishii (2002) address the ambiguity of accurately 
estimating the cost of stockouts and expiration cost as constant values when considering 
perishable inventory problems.  The researchers derived a single-period inventory model 
of perishable products using "fuzzy numbers" for the stockout and expiration costs.  The 
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authors introduce the fuzzy max order, derived by N. Furukawa (1994), to define non-
dominated ordering quantities for maximization of expected profits as solutions to the 
perishable inventory problem.   
Fredrik Olsson & Patrik Tydesjö (2010) expand upon the Schmidt and Nahmias 
(1985) research to consider a single perishable product with a Poisson demand, fixed life 
expectancy, and fixed replenishment lead time.  Fredrik Olsson & Patrik Tydesjö apply a 
(S-1, S) policy for stock replenishments. The authors consider three different cases 
where service level requirements are represented by stockout costs per unit, a service 
level constraint, and stockout costs per unit and time.  The authors conclude the study 
with a sensitivity analysis of the three cases using various parameter inputs. 
Inventory Management of Perishable Blood Donations  
 One of the earliest applications of the perishable inventory management research 
topic was on the management of whole blood units within local and regional blood 
banks.  Donated blood is a valuable commodity for medical treatment of conditions 
requiring transfusions.  The American Red Cross estimates that someone in the U.S. 
requires blood every 2 seconds of the day (www.redcrossblood.org).  The complexity 
surrounding the management of whole blood units is the requirement of needing a robust 
supply of the blood units on hand to respond to medical emergencies along with the 
constraint of its perishability.  Blood bank managers are faced with the daunting task of 
ensuring the availability of all blood type units for use in life saving procedures, while 
also attempting to limit the spoilage rate of such a valuable and limited resource.  The 
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review below will introduce a sample of research that was conducted in search of 
improving the effectiveness and efficiency of blood inventory management. 
 Gregory Prastacos (1984) provides a comprehensive overview of the theory and 
practice of blood inventory management.  One of the primary research efforts reviewed 
by Prastacos was conducted by J.B. Jennings.  Jennings (1968) used a simulation to 
evaluate blood bank performance and derive trade-off curves displaying the events of 
expiration vs. stockouts as functions of the inventory levels.  Prastacos suggests that the 
trade-off decisions between stockouts and expiration rates typically differ amongst the 
various blood types.  Because the demand rate of rarer blood types must be stocked 
proportionally higher than common blood types to achieve the same stockout rates, they 
result in higher expiration rates.   
A study of a large hospital in Philadelphia agreed with this notion as their 
expiration rates of rare blood types were dramatically higher than common blood types 
(Prastacos, 1984).  The author suggests that this finding justifies the common practice of 
some hospitals not to stock the rare types.  This generalization can be applied to the 
process of pharmaceutical formulary management.  In order to limit the degree of 
pharmaceutical expiration rates, the medical staffs of healthcare facilities should be 
selective in their decisions to add new pharmaceuticals to the formulary.  Additionally, 
medical staffs should conduct periodic reviews of their medical facilities’ formulary to 
determine if any currently stocked pharmaceuticals should be removed from the 
formulary with respect to a declining future patient demand. 
Dan Chazan & Shmuel Gal (1977) approach the blood inventory  management 
quandary by using a Markovian model to compute the upper and lower bounds of the 
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average number of whole blood units exceeding its useful life expectancy versus a total 
number of inventory units in stock.  The Markovian model was chosen to answer the 
research question of determining how much inventory could be held, and therefore 
reduce the risk of stockouts, without significantly increasing the number of blood units 
being discarded based on it exceeding its useful life expectancy. 
David Perry (1997) provides a unique approach by using a double band control 
policy to model the blood bank perishability problem.  With the number of items 
arriving during the age of the oldest item representing the model's stock level, the stock 
level of whole blood units is assumed to fluctuate as an alternating two-sided regulated 
Brownian motion between  the barriers of expiration (represented by a value of 0) and 
stockout (represented by a value of 1).  The model also assumes that the decision maker 
of the blood bank is able exercise control on the rates of arrival and demand.  Therefore, 
the model includes two switchover levels that are positioned between the values of 0 and 
1 (0 ≤ a < b ≤ 1).  When the stock levels reach the determined levels of a or b, the model 
assumes that the manager of the blood bank implements the appropriate measures to 
alter the arrival or demand of the blood units. 
Inventory Management of Perishable Pharmaceuticals 
While there is currently not a significant amount of extant literature dedicated to 
the management of pharmaceutical inventories, it is a research topic that has recently 
been pondered by a growing number of operations research analysts.  Although the 
majority of pharmaceuticals possess a longer fixed life expectancy than that of whole 
blood units, the inventory management of both products share the difficult tradeoff 
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decision between the requirements for maintaining a robust on hand inventory to meet 
patient demand with the conflicting constraint of limiting the waste associated with 
product expiration.  The trade-off decision between costs and the level of required 
service is more complex and difficult to manage in the health care setting than it is in the 
manufacturing industry.   
While the impact of stockouts in the manufacturing industry can be significant 
through the threat of lost sales, a stockout of critical pharmaceuticals and whole blood 
units can be harmful to the wellbeing of a patient in need. Although stockouts of blood 
units typically pose a more immediate threat to the health of patients in need, the impact 
of understocking pharmaceuticals can lead to increased dissatisfaction of physicians and 
a declining operational performance of the overall health care facility (Vries, 2011).  J. 
Vries states that a proper balance between service metrics and costs is without a doubt 
the main logistical challenge that hospitals are faced with. 
 Another complexity that the inventory management of blood units and 
pharmaceuticals share stems from the fact that they both possess product demand rates 
that exhibit non-stationary behavior. There are three factors that cause patient demand of 
pharmaceuticals to be non-stationary.  These factors include the change in patient 
condition dynamics, seasonalities, and the shifting of dosing requirements triggered by 
changes in patient characteristics such as age, weight, and blood pressure.  Additionally, 
pharmaceutical demand is a function of the patient population mix from which the health 
care facility services.  Despite the non-stationary behavior of pharmaceutical demand 
rates, early research on the topic of pharmaceutical inventory management treated the 
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demand rates as stationary and therefore possesses a lessened degree of validity (Vita-
Parrish & Ivy, 2013). 
 Vita-Parrish & Ivy (2013) provide a detailed summary of three unique studies that 
treated the pharmaceutical demand rate as stationary.  Little & Coughlan (2008) 
developed a stock level optimization model that accounted for storage space constraints, 
item criticality, and delivery frequency.  One of the primary findings by Little & 
Coughlan was that the same patient service levels can be achieved by receiving 
replenishment deliveries on a daily basis with low space usage compared to the receipt 
of replenishment deliveries every three to five days with a high space usage.   Claudia 
Rosales (2011) compared out-of-cycle and continuous review (s, S) replenishment 
policies of pharmaceuticals.  Rosales’ study concluded that a hybrid policy composed of 
the primary (s, S) policy and an out-of-cycle replenishment of a fixed order if stock 
positions reached a specified threshold was optimal.  Derrek Descioli (2005) studied the 
performance of various inventory control policies within automated point-of-use systems 
under the condition of intermittent demand rates.  The intermittent demand rates used in 
Descioli’s model was a progressive step towards a dynamic demand model that 
incorporates non-stationary demand. 
Anita Vila-Parrish, Julie Ivy, & Russell King (2008) were the first credited 
researchers to approach the inventory management of pharmaceuticals topic with a non-
stationary demand rate.  Vila-Parrish, Ivy, & King used a simulation based approach to 
model the inventory and ordering policies of an inpatient hospital pharmacy, where the 
model defines the patient demand of the individual pharmaceuticals as a function of the 
patient's condition.  The study includes simulations of stationary and non-stationary 
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demand rates for comparison.  The first policy, termed the "Fixed Policy", forecasts 
patient demand of pharmaceuticals based solely on historical demand.  The second 
policy, termed "Adaptive Policy" uses the number and type of patient admitted to the 
inpatient facility.  The results of the simulation show that the "Adaptive Policy" resulted 
in a lower total cost when compared to the "Fixed Policy" within the defined experiment 
set. 
 Vila-Parrish et al. (2012) expanded their previous study by modeling two stages 
of inventory with a production stage.  The two separate stages of inventory come in the 
forms of raw materials and finished goods (e.g. intravenous medications), where the 
production stage transforms the raw materials into the finished goods.  While 
deterministic, the life expectancy of a pharmaceutical is dependent upon its respective 
inventory stage.  For example, the raw materials have a shelf life of up to one year while 
the finished goods have an unrefrigerated shelf life of less than one day.  While the two 
stage inventory model expanded the body of knowledge concerning the pharmaceutical 
inventory management practices, it does not apply to this study based on its focus of 
pharmaceuticals remaining in just one inventory stage (raw materials). 
Summary 
 Chapter 2 provided a review of the relevant literature pertaining to the research 
pursuit of determining inventory control policies that provides the optimal mix between 
the minimization of inventory cost and the on hand availability of product for potential 
customer demand.  The literature review was segregated into research studies performed 
on the inventory management principles of non-perishable products and perishable 
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products.  Despite the fact that pharmaceuticals represent the later, the decision to 
include a review of non-perishable products was made based on the foundation it 
provided for the more complex study of perishable products.  The review of inventory 
management principles pertaining to perishable products was further segregated into an 
overview of fundamental studies focusing on the generalities of perishable items 
followed by the extant research conducted on the inventory management of donated 
blood units and pharmaceuticals.  While the stringent assumptions imposed on the 
models reviewed in Chapter 2 do not lend to complete applicability in this particular 
study, it provides a foundation from which the methodology will be based.  Chapter 3 
will detail the methodology used to evaluate the research questions posed in Chapter 1.  
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III.  Methodology  
Overview 
 The purpose of this chapter is to present the inventory management methodology 
used in this study.  The chapter begins by describing the data sets that were required to 
perform the inventory management methodology, as well as the process used for 
collection.  Following this, the chapter will outline the steps taken to estimate the 
historical inventory positions of the chosen MTF/pharmaceutical combinations, compute 
alternative stock levels, and finally to evaluate the results of the alternative stock levels 
in terms of cost savings and fill rates. 
Data Collection 
 The basic inventory management methodology used in this study required four 
distinct sets of data.  Serving as the primary motivation for the study, the first set of data 
collected in the effort represented the identification of expired or nearly expired 
pharmaceuticals that were turned in by AFMS MTFs during the time period of 
September 2012 through September 2014.  This data set, provided by the 
AFMOA/SGAL office, identified the turn-in of 15,098 unique pharmaceuticals with a 
replacement value of $23,168,655.02.  Because analysis of 15,098 individual 
pharmaceuticals at 81 dispensing locations was unfeasible given the time constraint for 
the study, a decision was made to narrow the scope of the study to a more manageable 
task.   
As a result, a focus was placed on the top 59 pharmaceuticals accounting for the 
largest turn-in values amongst CONUS MTFs.  Out of the top 59 pharmaceuticals 
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identified, 27 pharmaceuticals were further eliminated from the scope of the study based 
on War Reserve Material requirements, a discontinuance of patient demand during 2014, 
and other disqualifying factors such as the atypical procurement process of influenza 
vaccinations.  Table 2 displays the 32 pharmaceuticals that were ultimately chosen for 
inventory analysis.  The study performed inventory analysis on the 32 identified 
pharmaceuticals at up to ten MTFs, accounting for the largest portions of the turn-in 
value.  For example, the top 10 out of 17 MTFs returning Premarin 1.25 mg tablets were 
analyzed, whereas all 5 of 5 MTFs returning the Combivent 4 g Inhaler were analyzed. 
Table 2:  Pharmaceuticals Chosen for Inventory Analysis 
Pharmaceuticals 
●  Abilify 30 mg Tablet ●  Levitra 10 mg Tablet 
●  Acetasol HC Ear Drops ●  Mefloquine 250 mg 
●  Advair 250-50 Diskus ●  Nexium DR 40 mg Tablet 
●  Agrylin 0.5 mg Capsule ●  Pancreaze DR 16,800 UU Capsule 
●  Avonex 30 mcgs ●  Premarin 0.3 mg Tablet 
●  Celebrex 100 mg Capsule ●  Premarin 0.625 mg Tablet 
●  Celebrex 200 mg Capsule ●  Premarin 1.25 mg Tablet 
●  Combivent Respimat Inhaler 4 g ●  Prograf 5 mg Capsule 
●  Epipen 2-pack 0.3 mg Auto-Injector ●  Sandostatin Lar 30 mg 
●  Fosamax Plus D 70 mg--2,800 IU UU ●  Spiriva 18 mcg CP-Handihaler 
●  Fosamax Plus D 70 mg--5,600 IU UU ●  Tamiflu 75 mg  
●  Gleevec 100 mg Tablet ●  Tobradex Eye Drops 5 ml 
●  Gleevec 400 mg Tablet ●  Votrient 30 mg 
●  Glucagon 1 mg ●  Vytorin 10-10 mg Tablet 
●  Januvia 100 mg Tablet ●  Zemplar 4 mg 
●  Lamictal XR 100 mg Tablet ●  Zytiga 250 mg Tablet 
 
 The second set of data collected represents the historical patient demand for the 
MTF/pharmaceutical combinations that were identified for analysis.  The data set that 
was found to most closely represent the historical patient demand for the identified 
MTF/pharmaceutical combinations was the dispensing records from each of the 
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respective MTF pharmacies.  While this data set does not include any unfilled patient 
demand that may have occurred during the time period of 1/1/2012 through 9/19/2014, it 
is substantially representative of the overall patient demand.  The MTF pharmaceutical 
dispensing records were provided by the 711th Human Performance Wing through an ad 
hoc query within the Military Health System Management Analysis and Reporting Tool 
(M2).   
 The third set of data collected for the study represents the procurement of the 
identified pharmaceuticals from the PPV.  This recorded activity signifies the respective 
MTF pharmacies receiving a resupply of stock to counterbalance previous patient 
disbursements of the pharmaceuticals being studied.  This data set was then converted to 
match the units of supply found within the patient demand data.  For example, one bottle 
of the Celebrex 100 mg pharmaceutical was converted to represent the 500 tablets 
contained within the PPV supplied bottle.  The PPV sales of the identified 
pharmaceuticals was provided by the AFMOA/SGAL office through an ad hoc query 
within the DMLSS system. 
 The fourth and final data set that was required to be collected for the inventory 
analysis study was the suggested stock levels for the MTF/pharmaceutical combinations 
as found in the DMLSS CAIM module.  These suggested stock levels were sought as an 
estimation of the 1/1/2012 beginning inventory positions in lieu of the actual beginning 
inventory position not being available for use in this study.  The use of the suggested 
stock levels was chosen as a conservative approach based on the likelihood that it 
understates the actual beginning inventory positions found on 1/1/2012.  Therefore, the 
suggested stock levels were used as the beginning 1/1/2012 inventory position unless it 
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was discovered to be insufficient in providing estimated inventory positions that did not 
fall below zero during the time frame of the study.  Inventory positions falling below 
zero, signifying a stockout, were not permitted to occur in the estimated timeline of 
inventory positions because the data set representing patient demand included only 
demand that was filled. The suggested inventory stock level data set was also provided 
by the AFMOA/SGAL office through an ad hoc query of the DMLSS system.  
Estimation of Historical Inventory Positions 
The first step required to perform the cost savings comparison analysis was to 
determine the existing inventory state upon which a comparison was to be drawn from.  
As previously discussed, daily inventory positions for the MTF/pharmaceutical 
combinations were not available for use in the study.  Therefore, an estimation of the 
historical inventory positions were drawn in accordance with the data that was made 
available for the study.  The calculations found in Equation 2 were used to estimate the 
historical daily inventory positions of the respective MTF/pharmaceutical combinations.  
 It should be noted that the pharmaceutical returns data used in Equation 2 begins 
in September 2012 and not 1/1/2012.  This is based on the idea that the daily inventory 
position estimates begin on 1/1/2012 with fresh stock that would not be returned to the 
reverse logistics vendor during the early portion of the study’s timeline.  Occurrences in 
September 2012 represent a realistic time frame upon which unused stock from the start 
of the timeline would be nearing or past expiration and therefore warrant inventory 
return actions.  Additionally, the number of units procured from the PPV is represented 
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by the previous duty day’s order request for the respective pharmaceutical.  This is based 
on the PPV’s 24 hour delivery lead time that was previously discussed in Chapter 1. 
Ii = (Iі-1 + P) – (D + R)    (2) 
Where 
I = Inventory Position 
P = Number of Units Procured from the PPV 
D = Number of Units Demanded 
R = Number of Units Returned 
 After the estimated daily inventory position for days 1/1/2012 through 9/19/2014 
were calculated, an average inventory position was calculated.  Figure 4 displays a 
graphical representation of the estimated daily inventory position timeline for Premarin 
0.625 mg at Altus AFB. 
 
Figure 4:  Daily Inventory Position Timeline for Premarin 0.625 mg at Altus AFB 
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Calculation of an Alternative Order-Up-To Stock Level  
The next phase of the methodology is the calculation of an alternative stock level 
for the respective MTF/pharmaceutical combination.  Guided by the study’s research 
questions, the primary objectives in determining an alternative stock level is that it 
achieves expiration and on-hand inventory savings for the MTF, while limiting the 
number of potential stockout occurrences that are typically associated with lower levels 
of stock.  Based on these objectives, Equations 3 through 5 were chosen to generate an 
appropriate pharmaceutical stock level. 
S = LTD + Isafety     (3) 
 
Where 
S = Order-Up-To Stock Level  
 
LTD = Average Lead Time Demand 
 
Isafety = Safety Stock 
 
 
LTD = LR      (4) 
 
Where 
 
L = Average Replenishment Lead Time 
 
R = Average Demand Rate (Mean) 
 
 
Isafety = t�(𝐿 ×  𝜎𝑅2) + (𝑅2  ×   𝜎𝐿2)    (5) 
 
Where 
 
t = Service Level Factor 
 
𝜎𝑅2 = Variance of Demand 
 
𝜎𝐿2 = Variance of Lead Time 
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 Based on the assumption that the average delivery lead time is fixed at one day 
(24 hours) with a lead time variance of zero, the safety stock calculation seen in 
Equation 5 is reduced to the desired service level factor multiplied by the standard 
deviation of demand for the purposes of this study.  The Type 2 service level factor 
component of the equation is represented by the t statistic that corresponds to the desired 
fill rate (Shivsharan, 2012:6).  The t statistic was chosen over the more commonly used z 
statistic based on the fact that a significant number of the MTF/pharmaceutical 
combinations analyzed in this study possess less than 30 separate days of product 
demand greater than zero.  Additionally, the choice of the t statistic errs on the side of 
caution by providing a more conservative approach.  This is based on the fact that it 
provides a slightly higher calculation of safety stock for those pharmaceuticals 
possessing 30 or more separate days of product demand greater than zero.  
 As evidenced by the use of the t statistic, Equation 5 assumes a normal or nearly 
normal distribution of demand.  The use of this equation with the normality assumption 
is common practice within industry, despite the fact that the actual distribution of 
demand rarely follows such a distribution.  This common disregard towards the likely 
violation of the normality assumption is typically considered to be acceptable based on 
the argument that a more complicated yet accurate representation of the demand during 
lead time may be ineffectual because its gain in precision is comparatively small (Silver 
& Peterson, 1985:289).  Based on this argument and its common use within industry, the 
use of Equation 5 with an assumed normal distribution of demand is justified despite the 
likely violation of the assumption. 
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 The calculations captured in Equations 3 through 5 are applied to the respective 
patient demand data for the two year time period of 1/1/2012 through 12/31/2013.  Days 
that generated zero demand are eliminated from the calculations based on the fact that 
the service level factor represents the pharmaceutical fill rates.  Because fill rates are not 
computed on days with zero demand, the decision to remove these days from the order-
up-to stock level calculation is valid.  Table 3 displays an example of the calculations 
performed in determining the appropriate order-up-to stock level for the 200 mg variant 
of the Celebrex pharmaceutical at Goodfellow AFB.  In this example, the order-up-to 
level is calculated to be 825.363 tablets.  However, this value is rounded up to the 
nearest unit of sale from the PPV (bottle of 500 tablets). 
Table 3:  Order-Up-To Level Calculation for Celebrex 200 mg at Goodfellow AFB 
Goodfellow AFB--Celebrex 200 mg 
Calculation Value Units 
Days w/ Demand > 0 246 days 
L 1 day 
R 267.862 tablets 
LTD 267.862 tablets 
σ R 178.467 tablets 
T-statistic (99.9%) 3.123828683 
Isafety 557.501 tablets 
Order-Up-To Level (S) 825.363 tablets 
S (Rounded) 1,000 tablets 
 
Evaluation of the Alternative Stock Level 
 After the alternative order-up-to stock levels for each MTF/pharmaceutical 
combination has been calculated, the final phase of the study’s methodology is to 
evaluate it in terms of potential cost savings and pharmaceutical fill rates.  This 
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evaluation is performed by testing the performance of the revised stock levels in 
response to the MTF/pharmaceutical’s historical demand over the time period of 1/1/14 
through 9/19/14.  In this testing phase, the ending daily inventory position is calculated 
in the same manner as stated in Equation 1.  Additionally, it is assumed that the MTF 
operates a (R, S) inventory control policy where inventory positions are reviewed at the 
end of each duty day.  If during the review it is found that a respective pharmaceutical’s 
inventory position has fallen below the alternative order-up-to stock level, an order is 
placed through the PPV that day with a delivery occurring the following morning of a 
duty day.  The PPV order will be placed for the quantity that is necessary to bring the 
following duty day’s beginning inventory position (after the morning PPV delivery) to a 
quantity that meets the alternative order-up-to stock level.  Figure 5 provides a graphical 
illustration of the daily inventory positions for the Combivent 4g pharmaceutical at 
Shaw AFB, utilizing the calculated alternative order-up-to stock level of 12 units. 
 
Figure 5:  Example of Inventory Position Using the Alternative Stock Level 
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 The next step in the evaluation process is to determine the Inventory Turnover 
(ITO) rates that the alternative order-up-to stock levels would have provided in the time 
period between 1/1/2014 and 9/19/2014.  The calculated ITO rates are then used as an 
indicator for estimating the potential amount of inventory that would exceed its 
expiration date of clinical effectiveness under the revised inventory control policy.  As 
previously discussed in Chapter 1, a conservative approach assumption is made for the 
study to apply a six month lifespan of clinical effectiveness for all pharmaceuticals 
procured through the PPV Generation III contract.  Based on this assumption, it can be 
reasoned that MTF/pharmaceutical combinations exhibiting an annual ITO of two or 
more will not require any reverse logistics returns for reasons of expiration.  Equation 6 
provides the procedure for calculating the ITO rate for the time period in question.   
ITO = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑉𝑎𝑙𝑢𝑒 ($)
𝐶𝑜𝑠𝑡 𝑜𝑓 𝐺𝑜𝑜𝑑𝑠 𝑆𝑜𝑙𝑑 ($)
    (6) 
 The components of Equation 6 are quite easily found.  Average Inventory Value 
is simply the unit cost multiplied by the average inventory position, whereas the Cost of 
Goods Sold is simply the summation of the number of pharmaceutical units dispensed to 
patients during the time period in question multiplied by the unit cost.  Because the 
evaluation time period does not cover an entire year, the calculated ITR must be 
converted into an annual ITO rate.  The time period of 1/1/2014 through 9/19/2014 
covers 262 of the total 365 days in the year, or approximately 0.717808 years.  Based on 
this, the ITO rates covering the time periods of 1/1/2014 through 9/19/2014 can be 
easily converted to an annual ITO rate by dividing it by 0.717808.   
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The next step in the evaluation process of the study’s methodology is to estimate 
the annual expiration savings for MTF/pharmaceutical combinations if the alternative 
order-up-to stock levels generated an annual ITO that exceeded two turns.  For those 
MTF/pharmaceutical combinations with an annual ITO exceeding a value of two, the 
estimated annual savings from a pharmaceutical perishability is calculated by simply 
dividing the respective combination’s actual return value by two.  The respective 
combination’s actual return value is divided by two based on the fact that the expired 
returns data set spanned 24 months from the 9/17/2012 through 9/16/2014.   
In addition to the potential savings related to the avoidance of pharmaceutical 
perishability, the alternative order-up-to stock levels also provide savings potential that 
is realized with a reduction of on-hand stock inventories.  While the estimated expiration 
savings has the potential to be perpetually realized on an annual basis, a reduction in on-
hand stock inventories realizes a one time savings.  Equation 7 displays the calculations 
used to estimate the potential on-hand inventory reduction savings from adopting the 
alternative order-up-to stock level.  It should be noted that the value used for P is the 
average of daily inventory positions that were estimated through the calculation of 
Equation 2.  
O = C × (P – S)     (7) 
Where 
O = On-hand Inventory Savings 
C = Unit Cost of the Pharmaceutical 
P = Average Historical Inventory Position  
S = Alternate Order-Up-To Stock Level 
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 While potential savings from the avoidance of expired pharmaceutical stock and 
on-hand stock reductions would be very appealing to DoD financial decision makers, the 
realization of these potential savings would be considered impractical if it resulted in a 
significant increase in pharmaceutical stockouts.  Therefore, the final calculation 
performed in this study’s methodology is that of a fill rate.  The fill rate is calculated by 
simply dividing the number of patient prescriptions that were filled by the total number 
of prescription demands placed by the patient for a given pharmaceutical.  For example, 
the pharmacy at Holloman AFB would have been able to fill 1,508 out of 1,512 requests 
for Nexium 40 mg tablets during the time period of 1/1/14 through 9/19/2014 if they 
operated under the alternative order-up-to stock level of 2,070 tablets.  Therefore, the 
pharmaceutical fill rate for Nexium at Holloman AFB was 1,508 divided by 1,512, or 
99.74%.  It should also be pointed out that the four stockouts that would occur for 
Nexium at Holloman AFB could be filled during the following duty day based on the 
one day delivery of the PPV. 
Summary 
 Chapter 3 provided a description of the methodology used to answer the research 
questions of this study.  The methodology began through the collection of four distinct 
data sets.  The patient demand, pharmaceutical vendor sales records, pharmaceutical 
returns and DMLSS CAIM suggested stock levels were all utilized for subsequent steps 
in the study’s methodology.  The pharmaceutical returns data was initially used to focus 
the scope of the study into a manageable undertaking.  A combination of all four data 
sets were used to establish an estimated timeline of daily inventory positions from the 
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time period of 1/1/2012 through 9/19/2014.  This estimated timeline of daily inventory 
positions provided a historical approximation of the respective MTF/pharmaceutical’s 
inventory state.  The patient demand data from 1/1/2012 through 12/31/2013 was later 
used to calculate an alternative order-up-to stock level for each of the 
MTF/pharmaceutical combinations.  The final step of the study’s methodology was 
performed when the alternate order-up-to stock levels were evaluated in terms of cost 
savings and fill rates, with respect to the patient demand data from the time period of 
1/1/2014 through 9/19/2014. 
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IV.  Results and Analysis 
Chapter Overview 
 This chapter summarizes the results derived from the methodology found in 
Chapter 3.  In addition to summarizing the bottom line results of the overall study, this 
chapter will provide in depth analysis on a sampling of the 173 MTF/pharmaceutical 
combinations studied.  The first MTF/pharmaceutical chosen for analysis provides 
opportunity for significant cost savings while also maintaining a 100 percent fill rate 
given the use of the calculated alternative order-up-to stock level.  The second 
combination chosen for analysis provides an opportunity for moderate cost savings 
while also delivering a nearly perfect fill rate.  The third MTF/pharmaceutical chosen for 
analysis provides a modest potential for cost savings while also delivering one of the 
lowest fill rates found in the study.  This chapter will also provide insight into the 
MTF/pharmaceutical combinations that were found to exhibit turnover rates that fell 
below 2. 
Travis AFB—Fosamax D 70 mg 5,600 IU 
 The examination of the Fosamax D 70 mg 5,600 IU pharmaceutical at Travis 
AFB revealed a substantial opportunity for cost savings.  Figure 6  displays the 
calculated estimate of the MTF/pharmaceutical’s daily inventory position over the time 
period of 1/1/2012 through 9/19/2014.  The starting inventory position of 1/1/2012 is 
represented by the DMLSS CAIM suggested stock level of 94 packages containing four 
tablets each (376 tablets).  As a result of a large number of purchases from the PPV in 
January and February 2012, the daily inventory position of the MTF/pharmaceutical 
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combination quickly escalated to approximately 1,500 tablets.  After maintaining this 
inventory position for approximately 12 months, the inventory position grew in March 
2013 to reach a high of approximately 2,150 tablets.  Two sizeable turn-ins of expired 
pharmaceuticals in May 2013 reduced the inventory position to a level that fell below 
1,000 tablets.  Throughout the estimated timeline, the Fosamax D 70 mg 5,600 IU 
pharmaceutical at Travis AFB exhibited an average inventory position of 1,420 tablets. 
 
 
Figure 6:  Daily Inventory Position Timeline for Fosamax D 70 mg at Travis AFB  
 With visual evidence suggesting that an average inventory position of 1,420 
tablets of Fosamax D 70 mg was excessive given the daily demand at Travis AFB, the 
next step was to calculate an alternative order-up-to stock level.  During the time period 
of 1/1/2012 through 12/31/2103, there were 333 days where at least one prescription of 
Fosamax D 70 mg 5,600 IU was demanded.  Applying Equation 3 to the patient demand 
of these 333 days, the LTD component was calculated at 16.8048 tablets with the Isafety 
component calculated at 27.4 tablets.  The addition of these two components produces 
the order-up-to stock level to a value of 44.2049 tablets.  Based on the Fosamax D 70 
mg 5,600 IU pharmaceutical being sold in packages of 4 tablets, the order-up-to stock 
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level is rounded up to 48 tablets.  Table 4 displays a summary of the order-up-to stock 
level calculations for Fosamax D 70 mg at Travis AFB. 
Table 4:  Order-Up-To Level Calculation for Fosamax D 70 mg at Travis AFB 
Travis AFB--Fosamax D 70 mg 5,600 IU 
Calculation Value Units 
Days w/ Demand > 0 333 days 
L 1 day 
R 16.8048 tablets 
LTD 16.8048 tablets 
σ R 8.79627 tablets 
T-statistic (99.9%) 3.114960539 
Isafety 27.4 tablets 
Order-Up-To Level (S) 44.2049 tablets 
S (Rounded) 48 tablets 
 
 The calculated alternative order-up-to stock level of 48 tablets was then applied to 
the patient demand during the time period of 1/1/2014 through 9/19/2014 and evaluated 
in terms of potential cost savings and fill rate.  Figure 7 displays the daily inventory 
position for Fosamax D 70 mg 5,600 IU at Travis AFB, given the use of the (R, S) 
inventory control policy with an order-up-to stock level of 48 tablets. 
 
Figure 7: Inventory Position Timeline for Fosamax D 70 mg at Travis AFB Using the Alternative 
Order-Up-To Stock Level in a (R, S) Inventory Control Policy 
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 The alternative order-up-to stock level provided an annual ITO rate of 33.09 
times.  Because the ITO rate exceeded a minimum of 2 turns, an annual savings from 
expired Fosamax D 70 mg 5,600 IU at Travis AFB was estimated at $8,370.18.  In 
addition to this annual savings, an estimated one time savings of $18,863.53 would be 
achieved by reducing the average inventory position of 1,420 tablets down to 48 tablets.  
In spite of the substantial inventory reduction, the Travis pharmacy would have been 
capable of filling all 98 of the prescription demands it experienced in the time period of 
1/1/2014 through 9/19/2014.  Table 5 provides a summary of the results found when 
applying the alternative order-up-to stock level of 48 Fosamax D 70 mg 5,600 IU tablets 
at Travis AFB. 
Table 5:  Evaluation Results of the Alternative Order-Up-To Stock Level for 
Fosamax D 70 mg 5,600 IU at Travis AFB 
Travis AFB--Fosamax D 70 mg 5,600 IU 
Measurement Results 
Inventory Turnover Rate 33.09 
Annual Expiration Savings $8,370.18  
On-Hand Stock Savings  $18,863.53  
Prescriptions Requested 98 
Prescriptions Filled 98 
Fill Rate 100% 
 
Wright Patterson AFB—Advair 250-50 Diskus 
 The examination of the Advair 250-50 Diskus pharmaceutical at Wright Patterson 
AFB revealed a moderate opportunity for cost savings.  Figure 8 displays the calculated 
estimate of the MTF/pharmaceutical’s daily inventory position over the time period of 
1/1/2012 through 9/19/2014.  The starting inventory position of 1/1/2012 is represented 
by the DMLSS CAIM suggested stock level of 9,804 individual diskus.  With a few 
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fleeting exceptions, the inventory position of Advair 250-50 Diskus at Wright Patterson 
was maintained within a range of 10,000 and 20,000 diskus during the time period of 
January 2012 through September 2013  On 9/17/2012, the Wright Patterson AFB 
pharmacy recorded a substantial turn-in of 6,000 expired Advair 250-50 diskus.  A 
major purchase through the PPV on 10/16/2012 resulted in the inventory position 
peaking at just above 30,000 diskus before it quickly returned back into the 12,000 to 
18,000 diskus range for the next 11 months.  During September 2013 through August 
2014, the inventory position once again expanded into a range between 21,000 and 
25,000 diskus.  From August 2014 through the end of the timeline, the inventory 
position declined and fell to a low of 7,824 diskus.  Throughout the estimated timeline of 
1/1/2012 through 9/19/2014, the Advair 250-50 pharmaceutical at Wright Patterson AFB 
exhibited an average inventory position of 17,354 diskus. 
 
Figure 8:  Daily Inventory Position Timeline for Advair 250-50 at Wright Patterson 
AFB (Historical Estimation) 
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 With visual evidence suggesting that an average inventory position of 17,354 
diskus of Advair 250-50 was excessive given the daily demand at Wright Patterson 
AFB, the next step was to calculate an alternative order-up-to stock level.  During the 
time period of 1/1/2012 through 12/31/2103, there were 688 days where at least one 
prescription of Advair 250-50 was demanded at Wright Patterson AFB.  Applying 
Equation 3 to the patient demand of these 688 days, the LTD component was calculated 
at 1,070.15 diskus with the Isafety component calculated at 1,840.25 diskus.  The addition 
of these two components produces the order-up-to stock level to a value of 2,910.40 
diskus.  Because it is impossible to have an order-up-to stock level of 2,910.40 diskus, 
the value was rounded to the nearest unit of sale.  Based on the Advair 250-50 
pharmaceutical being sold in cartons of 60 diskus, the order-up-to stock level is rounded 
up to 2,940 diskus.  Table 6 displays a summary of the order-up-to stock level 
calculations for Advair 250-50 at Wright Patterson AFB. 
Table 6:  Order-Up-To Level Calculation for Advair 250-50 at Wright Patterson 
AFB 
Wright Patterson AFB--Advair 250-50 
Calculation Value Units 
Days w/ Demand > 0 688 days 
L 1 day 
R 1070.15 diskus 
LTD 1070.145 diskus 
σ R 593.2213 diskus 
T-statistic (99.9%) 3.102138 
Isafety 1840.25 diskus 
Order-Up-To Level (S) 2910.4 diskus 
S (Rounded) 2,940 diskus 
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 The calculated alternative order-up-to stock level of 2,940 diskus was then 
applied to the patient demand during the time period of 1/1/2014 through 9/19/2014 and 
evaluated in terms of potential cost savings and fill rate.  Figure 9 displays the daily 
inventory position for Advair 250-50 at Wright Patterson AFB, given the use of the (R, 
S) inventory control policy with an order-up-to stock level of 2,940 diskus. 
 
Figure 9:  Inventory Position Timeline for Advair 250-50 at Wright Patterson AFB 
Using the Alternative Order-Up-To Stock Level in a (R, S) Inventory Control 
Policy 
The alternative order-up-to stock level provided an annual ITO rate of 113.53 
turns.  Because the annual ITO rate far exceeded the threshold of 2 turns, an annual 
savings from expired Advair 250-50 at Wright Patterson AFB was estimated at 
$4,605.94.  In addition to this annual savings, an estimated one time savings of 
$21,553.69 would be achieved by reducing the average inventory position of 17,354 
discus down to 2,940 diskus.  In spite of the substantial inventory reduction, the Wright 
Patterson pharmacy would have been capable of filling 1,436 of the total 1,437 
prescription demands it experienced in the time period of 1/1/2014 through 9/19/2014.  
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While not a perfect fill rate, this resulted in the very high fill rate of 99.93%.  Table 7 
provides a summary of the results found when applying the alternative order-up-to stock 
level of 2,940 Advair 250-50 diskus at Wright Patterson AFB. 
Table 7:  Evaluation Results of the Alternative Order-Up-To Stock Level for 
Advair 250-50 at Wright Patterson AFB 
Wright Patterson AFB—Advair 250-50 
Measurement Results 
Inventory Turnover Rate 113.53 
Annual Expiration Savings $4,605.94  
On-Hand Stock Savings  $21,553.69  
Prescriptions Requested 1,437 
Prescriptions Filled 1,436 
Fill Rate 99.93% 
 
Sheppard AFB—Tamiflu 75 mg 
 The examination of the Tamiflu 75 mg pharmaceutical at Sheppard AFB revealed 
a comparatively modest opportunity for cost savings.  Figure 10 displays the calculated 
estimate of the MTF/pharmaceutical combination’s daily inventory position over the 
time period of 1/1/2012 through 9/19/2014.  The Sheppard AFB/Tamiflu 75 mg 
combination is one of the examples where the DMLSS CAIM suggested stock level was 
not sufficient enough to prevent stockouts in the historical estimation.  Based on this, a 
starting inventory position of 960 tablets was chosen based on it representing the lowest 
stock level that prevented any stockouts from occurring in the historical estimation.   
With the exception two major transactions, there was very little activity that 
occurred with respect to the Tamiflu 75 mg pharmaceutical at Sheppard AFB over the 
first two years of the estimated historical timeline.  The two major transactions that took 
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place during those first two years was a purchase from the PPV in the amount of 480 
tablets on August 27, 2012 followed by a return 460 tablets of the Tamiflu 75 mg 
pharmaceutical on 3/14/2014.  However, the third year of the timeline experienced a 
larger amount of activity, temporarily bringing the inventory position down to zero.  
Throughout the estimated timeline of 1/1/2012 through 9/19/2014, the Tamiflu 75 mg 
pharmaceutical at Sheppard AFB exhibited an average inventory position of 698 tablets. 
 
Figure 10:  Daily Inventory Position Timeline for Tamiflu 75 mg at Sheppard AFB (Historical 
Estimation) 
The next step in the study’s methodology was to calculate an alternate order-up-to 
stock level.  During the time period of 1/1/2012 through 12/31/2103, there were 54 days 
where at least one prescription of Tamiflu 75 mg was demanded.  Applying Equation 3 
to the patient demand of these 54 days, the LTD component was calculated at 16.48148 
tablets with the Isafety component calculated at 32.3018 tablets.  The addition of these two 
components produces the order-up-to stock level to a value of 48.7833 tablets.  Based on 
the Tamiflu 75 mg pharmaceutical being sold in packages of 10 tablets, the order-up-to 
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stock level was rounded up to 50 tablets.  Table 8 displays a summary of the order-up-to 
stock level calculations for Tamiflu 75 mg at Sheppard AFB. 
Table 8:  Order-Up-To Level Calculation for Tamiflu 75 mg at Sheppard AFB 
Sheppard AFB--Tamiflu 75 mg 
Calculation Value Units 
Days w/ Demand > 0 54 days 
L 1 day 
R 16.48148 tablets 
LTD 16.48148 tablets 
σ R 9.93515 tablets 
T-statistic (99.9%) 3.251268 
Isafety 32.3018 tablets 
Order-Up-To Level (S) 48.7833 tablets 
S (Rounded) 50 tablets 
 
The calculated alternative order-up-to stock level of 50 tablets was then applied to 
the patient demand during the time period of 1/1/2014 through 9/19/2014 and evaluated 
in terms of potential cost savings and fill rate.  Figure 11 displays the daily inventory 
position for Tamiflu 70 mg at Sheppard AFB, given the use of the (R, S) inventory 
control policy with an order-up-to stock level of 50 tablets.    Looking at Figure 11, it is 
quite apparent that the calculated alternative order-up-to stock level of 50 was not 
substantial enough to prevent a significant number of stockouts that would have 
occurred at the beginning of the 2014 calendar year.  This is primarily due to the lower 
patient demand for Tamiflu 75 mg in 2012 and 2013 not providing a suitable prediction 
basis for the larger amount of patient demand that occurred in 2014.  
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Figure 11:  Inventory Position Timeline for Tamiflu 70 mg at Sheppard AFB Using the Alternative 
Order-Up-To Stock Level in a (R, S) Inventory Control Policy 
Despite the apparent failures of the calculated alternative order-up-to stock level 
for this MTF/pharmaceutical combination, the evaluation process within the 
methodology was pursued.  The alternative order-up-to stock level provided an annual 
ITO rate of 43.19 times.  Because the ITO rate far exceeded the threshold of 2 turns, an 
annual savings from expired Tamiflu 75 mg at Sheppard AFB was estimated at $331.81.  
In addition to this annual savings, an estimated one time savings of $1,401.89 would be 
achieved by reducing the average inventory position of 698 tablets down to 50 tablets.  
As was expected, the Sheppard pharmacy would have been capable of filling only 114 of 
the total 155 prescription demands it experienced in the time period of 1/1/2014 through 
9/19/2014 given an order-up-to stock level of 50 tablets.  This results in a very poor fill 
rate of 73.55%.  Table 9 provides a summary of the results found when applying the 
alternative order-up-to stock level of 50 Tamiflu 70 mg tablets at Sheppard AFB. 
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Table 9:  Evaluation Results of the Alternative Order-Up-To Stock Level for Tamiflu 75 mg at 
Sheppard AFB 
Sheppard AFB—Tamiflu 75 mg 
Measurement Results 
Inventory Turnover Rate 43.19 
Annual Expiration Savings $331.81  
On-Hand Stock Savings  $1,401.89  
Prescriptions Requested 155 
Prescriptions Filled 114 
Fill Rate 73.55% 
 
MTF/Pharmaceutical Combinations with Low Annual ITO Rates 
 Out of the total 173 MTF/pharmaceutical combinations analyzed in the study, 18 
of the combinations exhibited Annual ITO rates below 2 turns during the time period of 
1/1/2014 through 9/19/2014 given their alternative order-up-to stock levels.  Table 10 
displays these 18 combinations with the corresponding annual ITO rates. 
Table 10:  MTF/Pharmaceutical Combinations with Annual ITO Rates Below 2 
Pharmaceutical Base 
Avg. On-
Hand Savings 
Fill 
Requests Stockouts 
Fill 
Rate 
Annual 
ITO 
Acetasol HC Andrews $3,585.89  1 0 100% 1.39 
Avonex 30 mg Lackland $27,362.48  2 0 100% 0.76 
Fosamax D 70-2,800  Mt. Home $2,063.39  2 0 100% 1.04 
Fosamax D 70-5,600  Kirtland $4,272.68  1 0 100% 0.84 
Fosamax D 70-5,600 Maxwell $915.42  1 0 100% 0.22 
Gleevec 400 mg Keesler $14,930.42  2 0 100% 1.67 
Gleevec 400 mg Moody $2,585.76  2 0 100% 1.39 
Lamictal 100 mg Andrews $792.81  4 0 100% 1.28 
Lamictal 100 mg Kirtland $280.00  1 0 100% 0.08 
Lamictal 100 mg Seymour J. $24,582.32  0 0  N/A  0 
Mefloquine 250 mg Hill $1,805.43  3 0 100% 0.78 
Mefloquine 250 mg Lackland $14,386.76  3 0 100% 0.09 
Mefloquine 250 mg Little Rock $355.25  4 0 100% 0.82 
Mefloquine 250 mg Offutt $1,455.25  3 0 100% 1.34 
Mefloquine 250 mg Robins $1,434.06  3 0 100% 0.47 
Pancreaze DR  Andrews $1,784.16  1 0 100% 1.25 
Sandostatin 30 mg Lackland $12,452.74  2 0 100% 0.93 
Zemplar 4 mg Lackland $10,159.68  1 0 100% 1.39 
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  Over the two year time period of September 2012 through September 2014, these 
18 MTF/pharmaceutical combinations accounted for $46,441.08 (average annual cost of 
$23,220.54) in pharmaceutical returns.  Based on their annual ITO rates being below the 
threshold of 2 turns per year, there is no way of completely eliminating perishability 
costs for these combinations given the calculated order-up-to stock levels.  With that 
stated, the alternative order-up-to stock levels for these 18 combinations would most 
certainly reduce the perishability cost to levels lower than was previously experienced.  
In addition a reduction in perishability costs, the use of the calculated order-up-to stock 
level would provide a one time on-hand inventory reduction savings of $125,204.50.   
Summary 
 Upon analysis of the 173 MTF/pharmaceutical combinations within the scope of 
this study, it was determined the use of an alternative order-up-to stock level in a (R, S) 
inventory control policy could save the AFMS a significant amount of money in cost 
reductions.  Table 11 displays a summary of the results generated by the 155 
MTF/pharmaceutical combinations that exhibited an annual ITO that exceeded the 2 turn 
threshold.  Using the alternative order-up-to stock levels would have provided an 
estimated annual perishability cost reduction of $419,504.10.   
In addition to the annual perishability cost savings, the study found that the 
adoption of the alternative order-up-to stock levels could provide the AFMS with a one-
time inventory reduction savings of approximately $1,769,138.82.  This figure includes 
the 155 MTF/pharmaceutical combinations with annual ITOs above 2 turns, as well as 
the 18 combinations with annual ITOs below 2 turns.  In spite of the inventory 
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reductions that would occur with the use of the alternative order-up-to stock levels in a 
(R, S) inventory control policy, the evaluation phase of the methodology determined that 
the overall fill rate amongst the studied MTF/pharmaceutical combinations would be 
above 99.8%.  A breakdown of the individual MTF/pharmaceutical combination results 
can be found in Appendix A through AF. 
Table 11:  Summary of Results by Pharmaceutical 
  Savings 1/1/2014 - 9/19/2014 
Pharmaceutical 
Annual 
Expiration 
Average  
On-Hand 
Fill Rate 
Requests Stockouts Fill Rate 
Abilify 30 mg $30,618.84  $69,790.13  72 1 98.61% 
Acetasol HC $13,465.13  $23,115.46  95 0 100.00% 
Advair 250-50 $11,423.82  $74,371.09  4,125 0 100.00% 
Agrylin 0.5 mg $15,929.75  $18,472.50  8 0 100.00% 
Avonex 30 mg $10,118.42  $47,398.02  32 0 100.00% 
Celebrex 100 mg $5,917.95  $94,270.77  1,784 0 100.00% 
Celebrex 200 mg $14,917.89  $66,560.13  320 0 100.00% 
Combivent 4 g $12,055.01  $30,953.02  512 3 99.41% 
Epipen $19,091.93  $133,359.48  2,581 13 99.50% 
Fosamax D 70-2,800 $15,795.77  $24,606.95  541 3 99.45% 
Fosamax D 70-5,600 $27,674.01  $57,703.05  285 2 99.30% 
Gleevec 100 mg $6,838.95  $21,481.59  18 0 100.00% 
Gleevec 400 mg $19,280.18  $14,914.51  41 0 100.00% 
Glucagon 1 mg $14,497.62  $79,772.01  928 6 99.35% 
Januvia 100 mg $3,760.20  $67,138.54  2,871 4 99.86% 
Levitra 10 mg $10,976.00  $70,597.37  33 0 100.00% 
Nexium 40 mg $23,078.00  $141,716.94  37,901 4 99.99% 
Pancreaze 16,800 IU $6,360.41  $38,323.89  113 1 99.12% 
Premarin 0.3mg $16,773.20  $87,245.01  1,143 0 100.00% 
Premarin 0.625 mg $16,276.67  $76,003.38  1,265 0 100.00% 
Premarin 1.25 mg $29,810.28  $87,867.18  498 0 100.00% 
Prograf 5mg $21,243.69  $58,137.21  14 0 100.00% 
Sandostatin 30 mg $3,913.85  $11,269.88  9 0 100.00% 
Spiriva 18 mcg $9,673.62  $73,976.60  5,601 11 99.80% 
Tamiflu 75 mg $13,032.38  $32,206.87  785 63 91.97% 
Tobradex 5 ml $8,678.88  $17,024.00  45 0 100.00% 
Votrient 30 mg $17,207.21  $10,357.55  4 0 100.00% 
Vytorin 10 mg $8,286.93  $60,222.12  541 0 100.00% 
Zytiga 250 mg $12,807.59  $55,079.07  28 3 89.29% 
Totals $419,504.10  $1,643,934.32  62,193 114 99.82% 
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 In the case of a MTF returning a pharmaceutical to the reverse logistics vendor 
prior to its expiration date, the MTF receives a credit to be used in future procurement of 
other pharmaceuticals through the PPV.  The amount of the credit is not a static figure 
and depends on factors such as the remaining lifespan of the pharmaceutical and the 
manufacturer’s unique return policy.  Despite the varying credit amounts received by 
MTF, a representative from the AFMOA/SGAL office provided an estimate of 
approximately 40% of the returned pharmaceutical’s retail value.  In response to the 
shifting credit returns rate experienced by MTFs, Table 12 displays the effective 
perishability cost savings of the studied MTF/pharmaceutical combinations given a 
credit returns range of 30 through 50 percent.   
Table 12:  Sensitivity Table for Effective Perishability Cost Savings 
Credit % Effective Perishability Cost Savings 
30 $293,652.87  
35 $272,677.67  
40 $251,702.46  
45 $230,727.26  
50 $209,752.05  
 
Table 12 extends the benefit of doubt and treats all returns of the studied 
combinations as possessing a remaining lifespan of clinical effectiveness upon the date 
of return and therefore triggering a credit to be issued.  Although unlikely that each and 
every one of the studied returns had not reached the end of its expiration date, the AFMS 
would achieve an effective perishability cost savings of approximately $209,752.05 on 
the low-end and $293,652.87 on the high-end each year by using the alternative order-
up-to stock level for the studied MTF/pharmaceutical combinations.  Assuming that the 
AFMOA/SGAL office estimate of a credit equaling 40 percent of the pharmaceutical’s 
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retail value, the AFMS would achieve a perishability cost savings of approximately 
$251,702.46 each year using the methodology found in Chapter 3. 
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V.  Conclusions and Recommendations 
Overview 
 The chapter begins by summarizing the study by answering the research questions 
that were posed in Chapter 1 and concludes with recommendations for action and future 
research. 
Summary of the Research and Answers to the Research Questions 
 This study analyzed a total of 173 MTF/pharmaceutical combinations with respect 
to their historical inventory practices over the time period of 1/1/2012 through 
9/19/2014.  At the conclusion of the analysis, it was determined that the respective MTF 
pharmacies were holding an excessive amount of pharmaceutical stock, given the 
contractual performance service agreements they held with their respective PPV.  The 
unique aspect of this study is that it was the first known to apply patient demand to the 
pharmaceutical inventory analysis, whereas previous efforts utilized prior PPV sales as a 
substitute for the demand function.   
The research effort applied a basic inventory management calculation to the patient 
pharmaceutical demand data as a means to determine an alternative order-up-to stock 
level for each of the respective MTF/pharmaceutical combinations.  The alternative 
order-up-to stock levels were then evaluated against the 1/1/2014 through 9/19/2014 
patient demand data in terms of cost savings and fill rates.  The ensuing estimated cost 
savings and fill rate results were then used to answer the three research questions posed 
in the study. 
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1. What cost savings can the AFMS realize in terms of reducing the amount of 
expired or near expired pharmaceutical returns, given the application of an 
inventory control system that utilizes adjusted order-up-to stock level quantities?  
 
Out of the 155 MTF/pharmaceutical combinations studied that exhibited an annual 
ITO rate exceeding the 2 turn threshold, it is estimated that the AFMS could save 
$419,504.10 annually.  Because the AFMS receives credits for the return of 
pharmaceuticals with a remaining lifespan, the effective savings rate realized by the 
AFMS would be less than the $419,504.10.  Using a conservative approach and 
assuming the unlikely event that all of the returns possessed a lifespan of clinical 
usefulness upon the return date, the effective savings for the 155 MTF/pharmaceuticals 
combinations ranged from $209,752.05 to $293,652.87. 
2. What cost savings can the AFMS realize in terms of reducing on-hand 
pharmaceutical stock, given the application of an inventory control system that 
utilizes adjusted order-up-to stock level quantities? 
 
Out of the 173 MTF/pharmaceutical combinations analyzed in this study, it was 
estimated that the use of the (R, S) inventory control policy with the calculated 
alternative order-up-to stock levels would provide the AFMS with a one time inventory 
reduction savings of $1,769,138.82. 
3. What impact will the proposed inventory control system have on pharmaceutical 
fill rates? 
 
Aggregated across the 173 MTF/pharmaceutical combinations analyzed in this 
study, it was determined that the overall fill rate would have exceeded 99.82 percent.  In 
other terms, the collection of MTFs studied would have been unable to fill 114 of the 
62,193 prescriptions that were demanded during the time period of 1/1/2014 through 
9/19/2014.  While the aggregated fill rate across all of the studied combinations is 
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reasonably high given the cost savings trade-off, there were two pharmaceuticals that 
exhibited undesirable fill rates, namely Tamiflu 75 mg and Zytiga 250 mg.   
The primary cause of the undesirable fill rates amongst these two pharmaceuticals is 
that the patient demand pattern changed considerably from the data used to calculate the 
alternative order-up-to stock level (1/1/2012 through 12/31/2013) to the data used to 
evaluate the alternative order-up-to stock level (1/1/2014 through 9/19/2014).  Because 
it is extremely difficult for statistical analysis to forecast extreme shifts in demand, the 
AFMS would continue rely on the expertise and experience of the clinical staff to 
provide inventory policy recommendations on pharmaceuticals whose demand is 
projected to change. For example, the clinical staff may have been alerted to a 
heightened flu season in 2014 and therefore made a recommendation for the pharmacy 
to modify the calculated order-up-to stock levels accordingly for the Tamiflu 75 mg 
pharmaceutical. 
Recommendations for Action 
 Based on the assumption that AFMS leadership regards a 99.82% fill rate as a 
palatable trade-off for the cost savings ascertained in this study, it is recommended that a 
pilot study be conducted with one or more of the MTF/pharmaceutical combinations 
identified in this research effort.  Conducting a pilot study on a small scale will allow 
AFMS leadership to evaluate the feasibility of implementing the proposed inventory 
control policy with a calculated alternative order-up-to stock level using patient demand.  
In addition to providing a mechanism for evaluating the inventory control policy’s 
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feasibility, a pilot study would allow AFMS leadership to evaluate changes in actual cost 
savings, fill rates, and patient satisfaction rates. 
 A secondary recommendation stemming from this research effort suggests that all 
pharmaceuticals exhibiting an annual ITO rate below 2 turns should be evaluated by the 
MTF’s clinical staff in terms of approving or disapproving its continuation on the 
clinic’s formulary.  While there are certainly cases where a pharmaceutical with an 
annual ITO rate below 2 turns should be retained on a pharmacy’s formulary (i.e., 
lifesaving pharmaceuticals in an inpatient hospital), there are other cases where the 
preservation of a slow-moving pharmaceutical on the MTF formulary is not cost 
effective or clinically warranted.  Given access to the costs associated with 
pharmaceuticals exhibiting low annual ITO rates, the MTF’s clinical staff will be 
provided the information necessary to make an appropriate tradeoff decision. 
Recommendation for Future Research 
 Future research related to this study includes: 
• A research effort that calculates the cost savings and fill rates in accordance with 
the strict utilization of the DMLSS CAIM suggested stock levels as the alternative 
order-up-to stock level in a (R, S) inventory control policy.  Comparing these cost 
savings and fill rate results to the results of this study would provide insight into 
determining if patient demand or previous PPV sales is the better method in 
calculating the order-up-to stock level quantities. 
 
• A pharmaceutical inventory and safety stock analysis that addresses segments of 
Air Force medicine that was not covered in this study.  Such segments include the 
inventory control policies of OCONUS MTFs, influenza vaccinations, and the 
pharmaceuticals which are stocked inherently for WRM or Medical Counter-
Chemical, Biological, Radiological, and Nuclear purposes (MC-CBRN) purposes. 
 
o An inventory and safety stock analysis of OCONUS MTFs will require 
additional factors to be considered, such as the potential for longer lead 
time demands and higher variability in vendor fulfillment rates. 
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o An inventory and safety stock analysis on seasonal influenza vaccinations 
will need to factor in the nuances of the AFMS’ flu vaccination 
procurement process and dissemination.  Such nuances include but are 
not limited to the small number of orders for comparatively large 
quantities and the base’s policy regarding the dissemination of the flu 
vaccinations to civilian employees of the base who are not covered by 
TRICARE. 
 
o An inventory and safety stock analysis on pharmaceuticals that are 
stocked inherently for WRM or MC-CBRN purposes, such as the 
Antidote Treatment Nerve Agent Auto-Injector (ATNAA), could be 
conducted in search of an inventory control policy that achieves cost 
savings over the status quo policies while also ensuring the highest level 
of availability as possible. 
 
• A study that examines the feasibility of implementing an inventory control 
system that, like the one proposed in this study, calculates the order-up-to stock 
levels in accordance with patient demand.  The feasibility study could also 
examine the impact that implementing the proposed inventory control policy 
would have on pharmacy operations.  One impact for analysis is the increase in 
order frequency that will occur as a result of implemented the proposed 
inventory control policy.  From 1/1/2014 through 9/19/2014, the proposed 
inventory control policy applied to the 173 MTF/pharmaceutical combinations 
would have increased the number of replenishment orders from 4,576 to 12,675. 
As an alternative to the implementation of the proposed inventory control policy 
being performed by Air Force personnel, a feasibility study concerning a 
movement towards a Vendor Managed Inventory (VMI) system for Air Force 
pharmaceuticals could be explored.  
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Appendix A ― Abilify 30 mg Results 
 
Abilify 30 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Eglin $465.98  $819.34  8 0 3.34 
Lackland $28,709.03  $44,906.12  14 0 4.76 
Luke $260.90  $9,164.06  13 1 6.69 
Patrick $258.62  $4,120.99  9 0 5.22 
Peterson $225.36  $3,536.99  6 0 4.64 
Randolph $698.97  $7,242.63  22 0 6.24 
            
Total $30,618.84  $69,790.13  72 1   
      Fill Rate 98.61%   
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Appendix B ― Acetasol HC Results 
 
Acetasol HC 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $0  $3,586  1 0 1.39 
Charleston $1,426  $1,229  9 0 4.18 
Lackland $204  $390  7 0 4.88 
Langley $2,241  $5,998  9 0 4.18 
Luke $2,706  $2,189  19 0 11.61 
Travis $4,546  $9,552  32 0 13.1 
Wright Patterson $2,343  $3,758  19 0 13.23 
            
Total $13,465  $26,701  96 0   
      Fill Rate 100.00%   
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Appendix C ― Advair 250-50 Results 
 
Advair 250-50 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Holloman $1,086  $12,709  338 0 54.74 
McConnell $543  $596  291 0 60.25 
McGuire $1,794  $9,117  431 5 74.39 
Robins $1,077  $5,669  451 1 69.66 
Sheppard $1,062  $2,186  400 0 69.51 
Tinker $897  $18,309  674 0 74.23 
Vance $359  $4,233  103 1 40.09 
Wright Patterson $4,606  $21,554  1437 1 113.53 
            
Total $11,424  $74,371  4125 8   
      Fill Rate 99.81%   
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Appendix D ― Agrylin 0.5 mg Results 
 
Agrylin 0.5 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Lackland $15,929.75  $18,472.50  8 0 3.76 
            
Total $15,929.75  $18,472.50  8 0   
      Fill Rate 100.00%   
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Appendix E ― Avonex 30 mg Results 
 
Avonex 30 mcgs 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $3,353.16  $29,895.91  28 0 13.93 
Lackland $0.00  $27,362.48  2 0 0.76 
Travis $6,765.26  $17,502.11  4 0 2.79 
            
Total $10,118.42  $74,760.50  34 0   
      Fill Rate 100.00%   
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Appendix F ― Celebrex 100 mg Results 
 
Celebrex 100 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Holloman $1,493.15  $5,291.23  85 0 25.08 
Maxwell $1,477.73  $4,136.82  212 0 51.47 
Sheppard $728.66  $25,230.00  188 0 31.36 
Tinker $1,108.29  $17,315.63  356 0 47.3 
Wright 
Patterson $1,110.14  $42,297.09  943 0 91.23 
            
Total $5,917.95  $94,270.77  1784 0   
      Fill Rate 100.00%   
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Appendix G ― Celebrex 200 mg Results 
 
Celebrex 200 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Goodfellow $14,917.89  $66,560.13  320 0 35.9 
            
Total $14,917.89  $66,560.13  320 0   
      Fill Rate 100.00%   
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Appendix H ― Combivent 4 gm Results 
 
Combivent 4 gm 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $45.60  $1,627.18  72 0 24.03 
FE Warren $80.84  $2,239.96  93 1 38.49 
Goodfellow $2,773.41  $1,647.02  64 1 30.45 
Seymour 
Johnson $8,607.96  $22,155.11  108 1 39.78 
Shaw $547.20  $3,283.75  175 0 50.62 
            
Total $12,055.01  $30,953.02  512 3   
      Fill Rate 99.41%   
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Appendix I ― Epipen Results 
 
Epipen  
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Eglin $2,800.71  $21,453.32  546 1 89.58 
FE Warren $1,503.06  $9,647.60  101 0 34.83 
Los Angeles $1,300.94  $615.93  73 0 24.15 
Langley $3,149.87  $17,623.18  651 4 87.87 
Luke $1,922.30  $8,582.42  350 1 70.43 
Maxwell $2,022.44  $55,888.92  251 5 72.66 
Mt. Home $2,543.64  $1,079.91  84 0 32.74 
Robins $2,353.07  $13,744.01  328 2 83.36 
Tyndall $1,495.92  $4,724.19  197 0 50.35 
            
Total $19,091.93  $133,359.48  2581 13   
      Fill Rate 99.50%   
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Appendix J ― Fosamax 70 mg / 2,800 IU Vitamin D Results 
 
Fosamax 70 mg / 2,800 IU Vitamin D 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $1,433.18  $2,024.63  27 0 12.69 
Barksdale $3,566.49  $2,297.50  22 0 10.22 
Keesler $749.07  $903.71  21 0 14.63 
Los Angeles $1,689.78  $1,531.45  34 0 17.07 
Luke $853.10  $2,063.39  2 0 13.06 
Mt. Home $0.00  $2,063.39  2 0 1.04 
Patrick $5,088.11  $12,153.79  352 0 52.24 
Travis $1,186.77  $984.15  20 0 11.94 
Tyndall $1,229.28  $2,648.33  63 3 29.43 
            
Total $15,795.77  $26,670.34  543 3   
      Fill Rate 99.45%   
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Appendix K ― Fosamax 70 mg / 5,600 IU Vitamin D Results 
 
Fosamax 70 mg -- 5,600 IU Vitamin D 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Barksdale $5,734.20  $3,838.08  4 0 3.34 
Eglin $1,754.01  $5,982.14  23 0 13.73 
Keesler $2,649.00  $7,949.72  6 0 3.13 
Kirtland $0.00  $4,272.68  1 0 0.84 
Langley $1,621.22  $7,586.95  61 0 22.67 
Little Rock $1,733.62  $2,239.55  11 0 9.19 
Luke $1,392.21  $3,393.59  8 2 6.08 
Maxwell $0.00  $915.42  1 0 0.22 
Offutt $3,195.48  $6,301.44  58 0 25.7 
Travis $8,370.18  $18,863.53  98 0 33.09 
Wright Patterson $1,224.12  $1,548.05  16 0 7.43 
            
Total $27,674.02  $62,891.15  287 2   
      Fill Rate 99.30%   
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Appendix L ― Gleevec 100 mg Results 
 
Gleevec 100 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Travis $6,838.95  $21,481.59  18 0 11.26 
            
Total $6,838.95  $21,481.59  18 0   
      Fill Rate 100.00%   
 
  
 
74 
Appendix M ― Gleevec 400 mg Results 
 
Gleevec 400 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Keesler $0.00  $14,930.42  2 0 1.67 
Moody $0.00  $2,585.76  2 0 1.39 
Travis $19,280.18  $14,914.51  41 0 22.12 
            
Total $19,280.18  $32,430.69  41 0   
      Fill Rate 100.00%   
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Appendix N ― Glucagon 1 mg Results 
 
Glucagon 1 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Buckley $3,520.38  $4,631.64  37 0 15.05 
Dover $280.68  $1,479.48  13 0 4.64 
FE Warren $409.68  $1,046.72  30 0 13.23 
Keesler $1,082.33  $5,697.52  66 0 26.67 
Lackland $2,339.90  $6,065.18  238 2 46.1 
Langley $1,086.92  $1,064.43  53 0 16.02 
Moody $582.45  $2,151.73  11 0 4.53 
Nellis $1,433.87  $10,968.92  115 0 36.82 
Travis $1,962.83  $28,418.93  161 2 55.03 
Wright Patterson $1,798.61  $18,247.46  204 2 57.27 
          57.27 
Total $14,497.62  $79,772.01  928 6   
      Fill Rate 99.35%   
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Appendix O ― Januvia 100 mg Results 
 
Januvia 100 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Goodfellow $1,068.60  $13,702.87  180 2 48.99 
Los Angeles $89.18  $5,069.19  264 0 72.54 
Malmstrom $718.28  $2,193.12  177 0 48.64 
Mt Home $538.71  $2,252.43  190 0 40.19 
Shaw $896.45  $7,415.23  530 2 78.61 
Travis $90.44  $25,947.83  1351 0 103.47 
Vance $358.56  $10,557.87  179 0 61.88 
            
Total $3,760.20  $67,138.54  2871 4   
      Fill Rate 99.86%   
 
  
 
77 
Appendix P ― Lamictal 100 mg Results 
 
Lamictal 100 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $0.00  $792.81  4 0 1.28 
Kirtland $0.00  $280.00  1 0 0.08 
Seymour J. $0.00  $24,582.32  0 0 0 
            
Total $0.00  $25,655.13  5 0   
      Fill Rate 100.00%   
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Appendix Q ― Levitra 10 mg Results 
 
Levitra 10 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Travis $10,976.00  $70,597.37  33 0 22.89 
            
Total $10,976.00  $70,597.37  33 0   
      Fill Rate 100.00%   
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Appendix R ― Mefloquine 250 mg Results 
 
Mefloquine 250 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Hill $0.00  $1,805.43  3 0 0.78 
Lackland $0.00  $14,386.76  3 0 0.09 
Little Rock $0.00  $355.25  4 0 0.82 
Offutt $0.00  $1,455.25  3 0 1.34 
Robins $0.00  $1,434.06  3 0 0.47 
            
Total $0.00  $19,436.75  16 0   
      Fill Rate 100.00%   
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Appendix S ― Nexium 40 mg Results 
 
Nexium 40 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Goodfellow $6,971.69  $12,963.57  1235 0 77.66 
Hill $1,477.56  $22,970.60  4557 0 121.09 
Holloman $1,309.68  $5,573.69  1512 4 93.7 
Little Rock $901.76  $1,623.82  4383 0 129.35 
MacDill $4,808.64  $50,876.17  7985 0 111.64 
Maxwell $1,298.52  $5,051.18  5765 0 129.32 
Robins $3,318.87  $12,266.13  5096 0 114.66 
Tinker $1,172.28  $27,828.08  5412 0 106.96 
Whiteman $1,819.01  $2,563.70  1956 0 101.87 
            
Total $23,078.00  $141,716.94  37,901 4   
      Fill Rate 99.99%   
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Appendix T ― Pancreaze 16,800 IU Results 
 
Pancreaze 16,800 UU 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $0.00  $1,784.16  1 0 1.25 
Eglin $1,356.75  $2,970.16  58 0 8.81 
Keesler $1,389.83  $3,936.63  6 0 2.51 
Lackland $1,714.55  $16,374.11  21 1 12.96 
Maxwell $268.32  $2,143.96  21 0 11.02 
Travis $1,630.97  $12,899.03  7 0 3.34 
            
Total $6,360.41  $40,108.05  114 1   
      Fill Rate 99.12%   
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Appendix U ― Premarin 0.3 mg Results 
 
Premarin 0.3 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Barksdale $3,826.68  $10,046.01  147 0 16.96 
Beale $1,061.51  $2,556.18  57 0 6.67 
Cannon $969.54  $2,832.62  23 0 2.39 
Langley $2,460.99  $15,722.26  175 0 20.27 
Little Rock $1,932.60  $3,795.10  144 0 16.76 
Luke $2,929.55  $20,548.14  236 0 28.67 
Scott $1,452.05  $5,670.29  168 0 19.4 
Seymour $726.02  $12,117.36  75 0 8.47 
Shaw $1,414.28  $13,957.05  118 0 14.08 
            
Total $16,773.20  $87,245.01  1,143 0   
      Fill Rate 100.00%   
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Appendix V ― Premarin 0.625 mg Results 
 
Premarin 0.625 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Altus $722.76  $12,426.04  35 0 4.1 
Barksdale $2,607.48  $13,328.42  331 0 36.71 
Langley $8,184.86  $27,240.37  183 0 21.68 
Little Rock $480.56  $6,318.22  270 0 32.98 
Minot $494.72  $434.55  34 0 3.8 
Moody $480.56  $7,055.24  128 0 12.52 
Wright Patterson $3,305.75  $9,200.54  284 0 32.78 
            
Total $16,276.67  $76,003.38  1,265 0   
      Fill Rate 100.00%   
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Appendix W ― Premarin 1.25 mg Results 
 
Premarin 1.25 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Barksdale $3,591  $13,043  140 0 16.58 
Columbus $2,158  $7,469  39 0 4.88 
Langley $5,127  $9,252  16 0 9.61 
Little Rock $1,452  $320  99 0 40.75 
Los Angeles $2,919  $4,480  7 0 4.39 
Luke $2,197  $15,486  64 0 7.8 
Robins $726  $5,660  41 0 5.18 
Seymour 
Johnson $4,335  $10,525  24 0 2.9 
Travis $4,403  $15,039  36 0 4.78 
Tyndall $2,903  $6,593  32 0 4.01 
            
Total $29,810  $87,867  498 0   
      Fill Rate 100.00%   
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Appendix X ― Prograf 5 mg Results 
 
Prograf 5 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Lackland $11,740.07  $13,796.89  8 0 4.7 
Wright Patterson $9,503.63  $44,340.32  6 0 2.61 
            
Total $21,243.69  $58,137.21  14 0   
      Fill Rate 100.00%   
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Appendix Y ― Sandostatin 30 mg Results 
 
Sandostatin 30 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Keesler $3,913.85  $11,269.88  9 0 4.18 
Lackland $0.00  $12,452.74  2 0 0.93 
            
Total $3,913.85  $23,722.62  11 0   
      Fill Rate 100.00%   
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Appendix Z ― Spiriva 18 mcg Results 
 
Spiriva 18 mcg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Barksdale $2,711.87  $22,259.02  629 0 89.14 
Goodfellow $2,770.47  $3,362.84  137 0 45.59 
Los Angeles $44.82  $2,085.01  144 0 52.81 
Malmstrom $411.39  $1,191.36  247 2 76.39 
Maxwell $1,450.25  $16,035.68  717 2 99.75 
Mt Home $41.16  $3,252.01  191 0 55.73 
Patrick $45.32  $6,623.57  1185 0 12.81 
Robins $1,305.60  $4,505.91  460 2 77.83 
Vandenberg $493.92  $1,690.42  156 4 50.28 
Wright 
Patterson $398.84  $12,970.78  1735 1 118.28 
            
Total $9,673.62  $73,976.60  5601 11   
      Fill Rate 99.80%   
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Appendix AA ― Tamiflu 75 mg Results 
 
Tamiflu 75 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Barksdale $1,228.76  $2,554.66  181 6 26.23 
Lackland $4,546.67  $16,294.80  294 16 37.06 
Langley $5,527.35  $9,218.76  92 0 18.45 
McConnell $600.00  $1,087.71  33 0 11.42 
Seymour 
Johnson $216.41  $550.44  18 0 6.27 
Sheppard $497.72  $1,401.89  155 41 43.19 
Vance $415.49  $1,098.61  12 0 4.53 
            
Total $13,032.38  $32,206.87  785 63   
      Fill Rate 91.97%   
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Appendix AB ― Tobradex 5 ml Results 
 
Tobradex 5ml 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Wright Patterson $8,678.88  $17,024.00  45 0 21.36 
            
Total $8,678.88  $17,024.00  45 0   
      Fill Rate 100.00%   
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Appendix AC ― Votrient 30 mg Results 
 
Votrient 30 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Travis $17,207.21  $10,357.55  4 0 2.2 
            
Total $17,207.21  $10,357.55  4 0   
      Fill Rate 100.00%   
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Appendix AD ― Vytorin 10 mg Results 
 
Vytorin 10 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $1,683.18  $12,108.50  25 0 11.15 
Barksdale $1,214.87  $6,199.59  37 0 16.87 
Buckley $1,306.10  $7,362.74  21 0 11.94 
Columbus $457.95  $1,337.17  4 0 2.79 
Langley $328.50  $11,055.92  34 0 15.79 
Maxwell $437.84  $1,039.24  250 0 57.58 
Mt Home $281.06  $458.98  17 0 10.45 
Sheppard $1,424.22  $6,463.78  34 0 11.84 
Travis $1,153.23  $14,196.20  119 0 33.16 
            
Total $8,286.93  $60,222.12  541 0   
      Fill Rate 100.00%   
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Appendix AE ― Zemplar 4 mg Results 
 
Zemplar 4 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Lackland $0.00  $10,159.68  1 0 1.39 
            
Total $0.00  $10,159.68  1 0   
      Fill Rate 100.00%   
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Appendix AF ― Zytiga 250 mg Results 
 
Zytiga 250 mg 
  Savings 1/1/2014 - 9/19/2014 
Base Annual Expiration Average On-Hand Requests Stockouts Turnover 
Andrews $1,952.87  $15,548.23  14 0 6.5 
Travis $10,854.72  $39,530.84  14 3 13.93 
            
Total $12,807.59  $55,079.07  28 3   
      Fill Rate 89.29%   
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Appendix AG ― Quad Chart 
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